Skip to main
RNXT

RenovoRx (RNXT) Stock Forecast & Price Target

RenovoRx (RNXT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

RenovoRx is a clinical-stage biopharmaceutical company with a strong potential for revenue growth and a focus on developing novel precision oncology therapies. With a current valuation that is attractive, the company's FDA-cleared RenovoCath medical device and its patented Trans-Arterial Micro-Perfusion therapy platform have the potential to drive significant revenue growth in 2026/2027. Positive progress in clinical drug development, along with a new CFO and consistent increase in active commercial cancer centers, further supports the potential for success in the company's phase III TIGeR-PaC trial and achieving its revenue targets. However, there are potential risks to consider, such as liquidity and regulatory approvals, that could impact the company's ability to achieve its goals.

Bears say

RenovoRx is currently undergoing a lot of changes, with a new CFO and strong progress in its clinical drug development and commercialization efforts. At first glance, the slower pace of patient enrollment in their Phase 3 trial may seem concerning, but their focus on recruiting patients with non-progressive disease after an initial induction phase could increase the likelihood of success. Additionally, their early adoption and expansion of commercial sites validate their revenue projections for 2026 and potential for significant growth in 2027. However, the loss on issuance of a financial instrument may indicate potential financial struggles for the company.

RenovoRx (RNXT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RenovoRx (RNXT) Forecast

Analysts have given RenovoRx (RNXT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, RenovoRx (RNXT) has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RenovoRx (RNXT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.